CEEOR · Medical devices
From device classification to reimbursement, without dead ends
We guide manufacturers, importers and distributors through MDR and IVDR compliance and through the reimbursement systems of Czechia and Slovakia — technical documentation, clinical evidence, EUDAMED registration and market access, handled by one team.
Services
Six areas that decide a device's fate
Most projects start in one of them and end up touching the rest. That is why we run them as one team — the reimbursement pathway shapes the clinical evidence, and the clinical evidence shapes the technical file.
Medical device reimbursement
Separately billed material (ZUM), prescription devices and procedure reimbursement — from choosing the pathway to negotiating with the State Institute for Drug Control (SÚKL) and health insurance funds.
02HTA and budget impact
Health technology assessment, health-economic modelling, budget impact analysis for Czechia and MER for Slovakia, systematic literature reviews.
03MDR and IVDR regulatory affairs
Technical documentation, classification, conformity assessment, notified body communication and a working post-market surveillance system.
04EUDAMED and UDI
Actor and device registration, SRN, UDI-DI and UDI-PI management, bulk XML output and data clean-up before the 28 November 2026 deadline.
05Clinical evidence
Clinical evaluation and CER, IVD performance evaluation, clinical investigations, PMCF and PMPF studies, data collection and analysis.
06QMS and ISO 13485
Quality management system implementation, certification audit preparation, risk analysis under ISO 14971 and certification body communication.
How we work
Five steps we repeat on every project
The sequence stays the same for a single device and for a portfolio of hundreds. What changes is depth, not logic.
In roughly half of our projects the device turns out to have a different reimbursement pathway than assumed. Reworking a dossier is cheaper than a failed procedure.
- 01
Intake and regulatory strategy
Qualification, classification, the applicable conformity assessment route and a map of reimbursement pathways in Czechia and Slovakia.
- 02
Plan and timeline
Concrete steps with deadlines, owners and effort estimates — including the points where a notified body, SÚKL or a medical society has to be involved.
- 03
Documentation and data
Technical documentation, clinical evaluation, literature review, health-economic model and budget impact analysis, in the form the reviewer expects.
- 04
Submission and negotiation
We file, defend and answer questions — with SÚKL, insurance funds, notified bodies and medical societies.
- 05
Life after market entry
Post-market surveillance, PMCF and PMPF, trend reporting, reimbursement maintenance and legislative monitoring.
Run documentation and reimbursement yourself — in MedaSet
MedaSet is our cloud application for medical device documentation. It walks you through CE and SÚKL documentation, reimbursement applications, budget impact modelling and EUDAMED XML output — with versioning, notifications and quality control.
- One place — technical documentation, reimbursement and clinical data
- Versions and alerts — no more hunting for the approved revision
- EUDAMED XML — no manual re-typing between systems
- Company-wide access — QA, RA, marketing and sales in one logic
- Three support levels — from self-service to full outsourcing
Why CEEOR
Science, practice and analytics in one place
CEEOR was founded in 2006 as a research company supporting health innovation for patients. We have been in health data and reimbursement ever since — first in pharma, today equally in med-tech.
Our team combines experience from the regulator and from industry. That is a practical difference: we know not only what the rules require, but how they are assessed.
FAQ
What clients ask first
We are a non-EU manufacturer. What do we need to enter the Czech and Slovak market?
An EU authorised representative, technical documentation compliant with MDR or IVDR, Czech (and Slovak) language versions of the labelling and instructions for use, actor and device registration in EUDAMED with a valid SRN, and — for most classes — a notified body certificate.
Reimbursement is a separate track with its own evidence requirements. Starting it after certification is the single most common cause of delay we see.
How different is Czech reimbursement from other EU markets?
The mechanics are country-specific. Devices used inside a healthcare facility are usually billed as separately billed material (ZUM) alongside a procedure; devices prescribed to patients follow a categorisation tree with defined reimbursement groups under Act No. 48/1997 Coll.
What travels well from other markets is the evidence: a solid budget impact model and comparative clinical data can be adapted. What does not travel is the pathway logic.
Do you work in Slovakia and the wider CEE region?
Czechia and Slovakia are our home markets — in Slovakia we prepare pharmacoeconomic analyses and MER. Through our network we also cover further Central and Eastern European markets; the exact scope is confirmed at project start.
Can you take over a project that is already under way?
Yes. A frequent starting point is a gap review of existing technical documentation or a stalled reimbursement dossier. We tell you what is missing, what is inconsistent and in what order to fix it.
Have a device and no clear route?
Tell us what the device is and where you are. We will come back with a first read on classification, reimbursement pathway and the nearest deadlines.